PUBLIC COMPANY
saveGILEAD SCIENCES INC
USupdated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Immutep, Molecular cut workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Gilead reveals partial clinical hold on 2 CAR-T cell therapy trialsGilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two studies for the CAR-T cell therapy KITE-753 in diffuse large B-cell l…fiercebiotech · 3d ago
- Biopharma cuts at manufacturing plants expected to affect 4,000+As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming staff at manufacturing locations in 2026 or the coming years, with BioNTec…biospace · 4d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.fiercebiotech · 6d ago
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsA patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.biopharma_dive · 7d ago
- Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStarGilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.biospace · 9d ago
- ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor ther…biospace · 10d ago
- Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s IcotydeGilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across…fiercebiotech · 10d ago
- Gilead strikes $1.3B upfront China deal for oral IL-23 drugGilead is going to Shanghai for its latest expansion in the hot inflammation market, dishing out $1.28 billion upfront to PepStar Therapeutics for a Phase 1 asset. The California biopharma is gaini…endpoints · 10d ago
- STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney generalGilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid programstat · 10d ago
comments(0)
5-min edit window · permanent after that